AVIR FY 2023 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$70M

Operating Income

-$164M

Net Income

-$136M

EPS (Diluted)

$-1.63

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$85M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$595M

Total Liabilities

$40M

Stockholders' Equity

$555M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$70M	-$62M	-12.3%
Operating Income	-$164M	-$131M	-25.7%
Net Income	-$136M	-$116M	-17.3%